MarketPeel
Insider Trading Intelligence
PM

Pratik S. Multani

ERAS
DIRECTOR · ERASCA, INC. · CIK 0001586894
FILING MIX · LIFETIME61%/39%
BUYS
28
SELLS
18
TOTAL VALUE
$328.6K
COMPANIES
2
ACTIVE SINCE
Apr 2020
HOLDINGS NOW
243,888
AVG SELL PX
$7.87
TRADE KIND
SHOWING 46 / 46
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Pratik S. Multani, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+40.00%+6.63%+0.12%+6.51%-3.25%
14d5+80.00%+10.70%+0.19%+10.51%+1.89%
30d5+40.00%+27.45%+1.27%+26.18%+24.35%
60d5+20.00%+16.41%+3.14%+13.28%+9.12%
90d5+20.00%+22.57%+1.30%+21.27%+32.86%
180d5+40.00%+8.68%+9.11%-0.43%-25.05%
1y5(1 pending)+25.00%+32.41%+14.57%+17.84%-20.18%
2y5(2 pending)+33.33%+24.96%+38.37%-13.42%-48.20%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ERAS · 29,888 shares · as of Jun 26, 2026
043,21786,433129,650172,86620222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 28 buys / 18 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ERAS
ERASCA, INC.
PURCHASEGRANT
Stock grant
29,88829,888Jun 26, 2026Jun 29, 2026View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
35,50035,500Jan 2, 2026Jan 6, 2026View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
214,000214,000Jan 2, 2026Jan 6, 2026View →
ERAS
ERASCA, INC.
PURCHASEGRANT
Stock grant
19,53219,532Jan 1, 2026Jan 5, 2026View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
10,720$9.06$97.1K68,149Dec 16, 2025Dec 17, 2025View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASE
Chief Medical Officer
29,33378,869Dec 15, 2025Dec 17, 2025View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
8,0000Dec 15, 2025Dec 17, 2025View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
10,00010,000Dec 15, 2025Dec 17, 2025View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
11,33322,667Dec 15, 2025Dec 17, 2025View →
ERAS
ERASCA, INC.
PURCHASEGRANT
Stock grant
120,000120,000Jun 24, 2025Jun 26, 2025View →
ERAS
ERASCA, INC.
SALEGRANT
Gift
6,200166,666May 23, 2025Jun 3, 2025View →
ERAS
ERASCA, INC.
PURCHASEGRANT
Gift
6,2006,200May 23, 2025Jun 3, 2025View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
34,00034,000Jan 2, 2025Jan 3, 2025View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
202,500202,500Jan 2, 2025Jan 3, 2025View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
8,850$8.28$73.3K46,765Dec 16, 2024Dec 17, 2024View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
6,0420Dec 15, 2024Dec 17, 2024View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASE
Chief Medical Officer
24,04255,615Dec 15, 2024Dec 17, 2024View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
8,0008,000Dec 15, 2024Dec 17, 2024View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
10,00020,000Dec 15, 2024Dec 17, 2024View →
ERAS
ERASCA, INC.
PURCHASEGRANT
Stock grant
60,00060,000Jun 20, 2024Jun 21, 2024View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
30,00030,000Jan 2, 2024Jan 3, 2024View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
180,000180,000Jan 2, 2024Jan 3, 2024View →
ERAS
ERASCA, INC.
PURCHASEGRANT
Stock grant
32,86732,867Jan 1, 2024Jan 3, 2024View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
8,00016,000Dec 15, 2023Dec 19, 2023View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
6,0426,042Dec 15, 2023Dec 19, 2023View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASE
Chief Medical Officer
14,04229,091Dec 15, 2023Dec 19, 2023View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
5,282$8.59$45.4K23,809Dec 15, 2023Dec 19, 2023View →
ERAS
ERASCA, INC.
PURCHASEGRANT
Stock grant
60,00060,000Jun 22, 2023Jun 26, 2023View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
24,00024,000Feb 1, 2023Feb 2, 2023View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
145,000145,000Feb 1, 2023Feb 2, 2023View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASE
Chief Medical Officer
6,0419,512Dec 15, 2022Dec 16, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
6,04112,084Dec 15, 2022Dec 16, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
2,089$3.25$6.8K7,423Dec 15, 2022Dec 16, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
2,227$3.07$6.8K7,285Dec 15, 2022Feb 17, 2023View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
108,7500Jul 20, 2022Jul 21, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
90,0000Jul 20, 2022Jul 21, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
108,750108,750Jul 20, 2022Jul 21, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
90,00090,000Jul 20, 2022Jul 21, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
147,5000Jul 20, 2022Jul 21, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
147,500147,500Jul 20, 2022Jul 21, 2022View →
ERAS
ERASCA, INC.
PURCHASEGRANT
Stock grant
40,00040,000Jun 22, 2022Jun 24, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
18,12518,125Feb 1, 2022Feb 2, 2022View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
108,750108,750Feb 1, 2022Feb 2, 2022View →
ERAS
ERASCA, INC.
PURCHASE
6,200$16.00$99.2K172,866Jul 20, 2021Jul 20, 2021View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
90,00090,000Feb 1, 2021Feb 2, 2021View →
ORIC
ORIC PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
147,500147,500Apr 23, 2020Apr 27, 2020View →
Other insiders · ERAS
Loading peer insiders…
About this filer
CIK 0001586894
ROLE
Director
PRIMARY
ERAS
COMPANIES
2
ACTIVE SINCE
Apr 2020
MARKETPEEL · /INSIDER/0001586894DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback